A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
Recruiting now · Phase 3 · Has a placebo group
Conditions studied: Respiratory Syncytial Virus (RSV)
In brief
The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
Key facts
- Study ID
- NCT07653100
- Run by
- Pfizer
- People needed
- 540
- Starts
- 2026-06-22
- Expected to finish
- 2027-01-25
- Last updated by the study team
- 2026-07-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Chettinad Hospital and Research Institute — Kelambākkam, Tamil Nadu, India (enrolling)
- BGS Global Institute of Medical Sciences (BGSGIMS) — Bangalore, Karnataka, India (enrolling)
- Radhakrishna Multispeciality Hospital and IVF Center — Bangalore, Karnataka, India (enrolling)
- Belagavi Institute of Medical Sciences - Belagavi — Belagavi, Karnataka, India (enrolling)
- Suyog Hospital — Nashik, Maharashtra, India (enrolling)
- Aakash Healthcare Private Limited — Dwarka, National Capital Territory of Delhi, India (enrolling)
- All India Institute Of Medical Sciences — New Delhi, National Capital Territory of Delhi, India (enrolling)
- Sir Ganga Ram Hospital — New Delhi, National Capital Territory of Delhi, India (enrolling)
- Maharaja Agrasen Superspeciality Hospital — Jaipur, Rajasthan, India (enrolling)
- SRM Medical College Hospital and Research Centre - Kattankulathur — Chengalpattu, Tamil Nadu, India (enrolling)
- Institute of Post Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital — Kolkata, West Bengal, India
- Institute of Post Graduate Medical Education & Research, SSKM Hospital — Kolkata, West Bengal, India
- King George Hospital — Visakhapatnam, Andhra Pradesh, India
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.